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Stimulation with tumor necrosis factor (TNF)a and interferon (IFN)c synergistically induced thymus- and activation-
regulated chemokine (TARC)/CCL17 production from HaCaT keratinocytes (KC). Inhibitors for nuclear factor kappa
B (NFjB), parthenolide, and Bay 11-7085, and an inhibitor of p38, SB202190, inhibited TNFa- and IFNc-induced
production of CCL17 by HaCaT KC. Surprisingly, an inhibitor of epidermal growth factor receptor tyrosine kinase,
PD153035, enhanced the production of CCL17 in HaCaT KC. Roxithromycin (RXM), a 14-membered ring macrolide,
suppressed CCL17 production by HaCaT KC induced by IFNc and TNFa. RXM partially suppressed p38 phosphor-
ylation and NFjB-driven luciferase activity induced by TNFa and IFNc. Degradation of inhibitor of nuclear factor
kappa B (IjB) a upon stimulation with IFNc and TNFa was not affected by the addition of RXM. Through elucidating
the mechanism of CCL17 production, our study indicates that RXM suppresses the production through the in-
hibition of p38 and NFjB, independent of the inhibition of IjB degradation.
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Thymus- and activation-regulated chemokine (TARC)/
CCL17 is a member of the CC chemokine group that is
constitutively expressed in the thymus and is produced by
monocyte-derived dendritic cells (Imai et al, 1996; Zlotnik
and Yoshie, 2000) and endothelial cells (Campbell et al,
1999). It is a ligand for CC chemokine receptor (CCR) 4 and
CCR8 and serves in the recruitment and migration of cells
expressing these receptors (Bernardini et al, 1998; Sallusto
et al, 1998). It is considered a Th2-type chemokine because
CCR4-expressing T cells mainly produce interleukin (IL)-4.
We focused on TARC/CCL17 production from keratinocytes
(KC), because TARC/CCL17 has been proven to be essen-
tial in skin inflammation (Reiss et al, 2001), its existence in
the epidermis has been shown (Kakinuma et al, 2001), and
the serum concentration of TARC/CCL17 is elevated in
several inflammatory skin diseases such as atopic derma-
titis, and mycosis fungoides (Kakinuma et al, 2001, 2003),
which suggested to us that TARC/CCL17 produced from
KC could be the key molecule in attracting inflammatory
lymphocytes to the skin.
Since Kudoh et al (1987, 1998) reported their effective-
ness in the treatment of diffuse panbronchiolitis (DPB),
macrolide antibiotics have been recognized for their anti-
inflammatory effects. Macrolides suppress the activity of
neutrophils (Oishi et al, 1994; Matsuyama et al, 1997),
production of IL-6 and IL-8 in bronchial epithelial cells
(Takizawa et al, 1995, 1997), and the function of macroph-
ages (Sugiyama et al, 1999). They also inhibit the production
of inflammatory cytokines by nasal epithelial cells (Fujita
et al, 2000). Their clinical effects in patients with dermato-
logical diseases, such as psoriasis (Komine and Tamaki,
2000) and prurigo pigmentosa (Yazawa et al, 2001), were
also reported. Recently, macrolides have been reported to
be effective against bronchial asthma (Shoji et al, 1999),
acting on eosinophils (Cui et al, 2001) and lymphocytes
(Noma and Ogawa, 2003), (Noma et al, 2001). Roxithromycin
(RXM) is one of the newly synthesized 14-membered ring
macrolide antibiotics that is effective in treating acne vulgaris
and bacterial infections (Bryskier, 1998). It is also effective in
treating DPB, and chronic sinusitis, probably due to its anti-
inflammatory effects (Scaglione and Rossoni, 1998).
In this study, we first investigated the signaling pathways
by which tumor necrosis factor (TNF)a and interferon (IFN)g
stimulate HaCaT KC to produce CCL17, and then tested the
ability of RXM to suppress CCL17 production by HaCaT KC.
Furthermore, we investigated the inhibitory effect of RXM on
various signaling molecules in order to elucidate the mech-
anism of the suppression of CCL17 production.
Results
TNFa and IFNc synergistically induced TARC/CCL17
production from HaCaT KC Either TNFa or IFNg alone
slightly induced TARC/CCL17 production from HaCaT KC,
and the addition of both of these cytokines synergistically
induced TARC/CCL17 production (Fig 1). Normal human KC
in a monolayer culture did not produce TARC/CCL17 in a
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vation-regulated chemokine; TNF, tumor necrosis factor
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similar way, as previously reported (Tsuda et al, 2004) (data
not shown).
Induction of TARC/CCL17 by TNFa and IFNc was sup-
pressed by the addition of nuclear factor kappa B (NFjB)
inhibitors, Bay 11-7085 and parthenolide, and the p38
inhibitor, SB202190, but not by the extracellular signal-
regulated kinase (ERK) inhibitor, PD98059. Addition of
the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor, PD153035, enhanced TARC/CCL17
production We incubated HaCaT KC with the inhibitors of
NFkB, p38 mitogen-activated protein kinase (MAPK), ERK
MAPK, or EGFR tyrosine kinase for 1 h before stimulation
with TNFa and IFNg. Supernatants were collected and sub-
jected to ELISA. Parthenolide and Bay 11-7085, inhibitors of
NFkB activation, and SB202190, the inhibitor of p38 MAPK,
strongly inhibited the induction of CCL17 production by
TNFa and IFNg, but PD98059, the inhibitor of ERK MAPK,
did not show a significant suppression, which suggests that
the induction of CCL17 production by TNFa and IFNg is
dependent on NFkB and p38 MAPK, but not on ERK
MAPK. Unexpectedly, the addition of PD153035, the inhibitor
of EGFR tyrosine kinase, caused a significant increase in
CCL17 production in HaCaT KC, suggesting that the phos-
phorylation of EGFR has an inhibitory effect on the produc-
tion of CCL17 by HaCaT KC (Fig 2a). These results indicate
that either NFkB or p38 is indispensable for TNFa and IFNg-
induced CCL17 production, whereas ERK is not, and that the
phosphorylation of EGFR induced by TNFa and IFNg inhibits
CCL17 production. We tried western blotting utilizing the
antibody against the phosphorylated tyrosine to observe the
tyrosine phosphorylation state of the whole EGFR molecule.
Stimulation with TNFa and IFNg time dependently enhanced
the intensity of the EGFR bands that appeared at the mo-
lecular weight of 170 kDa, and PD153035 completely abol-
ished these bands (data not shown).
Signal transducer and activator of transcription 1
(STAT1) dominant-negative gene transfer failed to sup-
press TNFa and IFNc-induced production of TARC/
CCL17 compared with STAT1 wild-type gene-trans-
ferred HaCaT cells To investigate the role of STAT1 in the
induction of TARC/CCL17 by TNFa and IFNg, we infected
HaCaT KC with an adenovirus vector encoding the STAT1
dominant-negative gene. The blocking of the STAT1
pathway by the STAT1 dominant-negative genes (AxC-
AdnSTAT1) did not cause any inhibition of TNFa and
IFNg-induced TARC/CCL17 production compared with the
induction in cells transferred with STAT1 wild-type genes
(AxCAwtSTAT1) (Fig 2b). The induction of TARC/CCL17 was
weaker when compared with non-transfected cells, prob-
ably because of the transfection procedure. This result
Figure 1
Tumor necrosis factor (TNF)a and interferon (IFN)c synergistically
induce thymus- and activation-regulated chemokine (TARC)/
CCL17 production from HaCaT keratinocytes (KC). HaCaT KC were
stimulated with TNFa alone, IFNg alone, or TNFa plus IFNg, and the
concentration of TARC/CCL17 in the supernatant was measured.
Figure2
Inhibitors for p38 mitogen-activated protein kinase (MAPK) phos-
phorylation, and nuclear factor kappa B (NFjB) activation, but not
inhibitors for epidermal growth factor receptor tyrosine kinase and
ERK MAPK, inhibited thymus- and activation-regulated chemokine
(TARC)/CCL17 production by HaCaT keratinocytes (KC). HaCaT KC
infected with adenovirus containing STAT1 dominant-negative
genes showed similar induction levels of TARC/CCL17 by tumor
necrosis factor (TNF)a and interferon (IFN)c as HaCaTcells infected
with adenovirus containing STAT1 wild-type genes. HaCaT KC were
incubated with a panel of inhibitors for 1 h before stimulation with TNFa
and/or IFNg. This condition has been previously shown to be effective
in suppressing these protein kinases. Supernatants were collected and
ELISA was performed (a). HaCaT cells were infected with adenovirus
containing AxCAwtSTAT1 or AxCAdnSTAT1, starved of serum for 24 h,
and stimulated with TNFa and IFNg. Supernatants were collected after
24 h and subjected to ELISA (b).
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indicates that STAT1 activation is not essential in the
induction of TARC/CCL17 production by TNFa and IFNg.
RXM suppressed TARC/CCL17 production induced by
TNFa and IFNc from HaCaT KC Supernatants from cul-
tured HaCaT KC stimulated with TNFa and IFNg with or
without RXM treatment were subjected to ELISA. RXM
suppressed the induction of CCL17 production at concen-
trations of 104 and 105 M. The effect was concentration
dependent, with almost 80% suppression at 104 M, and
60% suppression at 105 M, but was not significant at 106
M (Fig 3) or lower concentrations.
RXM suppressed NFjB-driven luciferase activity in-
duced by TNFa and IFNc We assumed that RXM sup-
presses NFkB transcriptional activation since NFkB was
shown to be involved in the induction of CCL17 production
by TNFa and IFNg. We transfected HaCaT KC with an
NFkB-driven luciferase construct together with a cytome-
galovirus (CMV) renilla luciferase construct. The relative
luciferase activity was calculated with CMV renilla luciferase
activity as a control. Additions of TNFa and IFNg caused an
almost 9-fold increase in NFkB activity. At 105 M, RXM
significantly suppressed TNFa- and IFNg-induced NFkB
activity in HaCaT KC (Fig 4a). These results suggest that the
stimulation of HaCaT KC with TNFa and IFNg leads to NFkB
activation, which was essential for CCL17 production. The
fact that RXM partially inhibited NFkB activation by TNFa
and IFNg indicated that the suppression of CCL17 by RXM
was partially dependent on its NFkB suppression.
We performed a similar experiment in normal human KC
in order to confirm the suppression of NFkB activation by
RXM, because HaCaT KC have been reported to have
abnormal NFkB signaling (Chaturvedi et al, 2001). RXM also
inhibited the induction of NFkB-driven luciferase activity by
TNFa and IFNg in normal human KC (data not shown).
Inhibitor of nuclear factor kappa B (IkB) is an inhibitory
protein that binds to NFkB. Upon stimulation, IkB is phos-
phorylated and subsequently degraded by the ubiquitin–
proteasome pathway. Western blotting with the IkBa anti-
body revealed that IkBa degradation occurred upon stim-
ulation with TNFa and IFNg in a time-dependent manner,
which was restored after 1 h. This time course of degrada-
tion was not affected by the addition of RXM (Fig 4b). IkB
degradation usually leads to NFkB activation. The fact that
RXM did not alter the course of IkB degradation suggests
that RXM suppresses NFkB activation independent of IkB
degradation, probably at the point after IkB degradation.
RXM suppressed the phosphorylation of p38 and ERK
MAP kinases activated by TNFa and IFNc To investigate
whether the phosphorylation of signaling molecules, includ-
ing p38, is affected by the addition of RXM, western blotting
was performed using monoclonal antibodies against phos-
phorylated forms of these signaling molecules. RXM par-
tially suppressed the phosphorylation of p38 MAPK induced
by TNFa and IFNg (Figs 5a and b), which showed significant
suppression at the 15 and 30 min time points. Phosphor-
ylation of ERK was also slightly suppressed (Figs 5c and d),
which showed significant suppression only at the 5-min
time point. But, it did not affect the phosphorylation of c-
Jun-N-terminal kinase (JNK) or STAT1 (Fig S1, Fig S2). p38
is crucial for the CCL17 production induced by TNFa and
IFNg as shown in Fig 1, which means that p38 could also be
the target of RXM.
We confirmed the suppressive effect of RXM on the
phosphorylation of p38 in normal human KC. Normal human
KC were incubated in keratinocyte-serum free medium
Figure 3
Roxithromycin (RXM) inhibited production of thymus- and activation-
regulated chemokine (TARC)/CCL17 by HaCaT keratinocytes (KC) in
a concentration-dependent manner. HaCaT KC, starved of FCS for 24
h, were stimulated with tumor necrosis factor (TNF)a (10 ng per mL) and
interferon (IFN)g (10 ng per mL). 104, to 108, and 106 M of RXM were
added with TNFa and IFNg. Supernatants were subjected to ELISA.
Figure4
Roxithromycin (RXM) suppressed tumor necrosis factor (TNF)-in-
duced nuclear facor kappa B (NFjB)-driven luciferase activity in
HaCaT human keratinocytes (KC). HaCaT KC were grown in minimal
essential medium (MEM) with 10% fetal calf serum (FCS) until they
became subconfluent. The NFkB-driven luciferase construct and
cytomegalovirus (CMV)–renilla luciferase construct were co-transfected
into HaCaT KC. RXM was added 2 h before transfection. Both lucif-
erase activities were measured utilizing the dual luciferase assay sys-
tem. Luciferase activity was normalized against renilla luciferase
activity, and the fold induction compared with the non-stimulated con-
dition is shown (a). HaCaT KC were starved of FCS for 24 h with or
without RXM, stimulated with TNFa and IFNg, and harvested after the
indicated time periods. Cell lysates were subjected to western blotting
with the rabbit polyclonal anti-IkBa antibody (b). Degradation of inhib-
itor of nuclear factor kappa B (IkB) induced by TNFa and IFNg was not
affected by the addition of RXM.
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(keratinocyte-SFM) without epidermal growth factor (EGF)
or bovine pituitary extract (BPE), with or without RXM for 24
h, and then stimulated with TNFa and IFNg for indicated
time periods. The phosphorylation of p38 was suppressed
when pre-incubated with RXM; phosphorylations of ERK,
JNK, and STAT1 were not affected by the addition of RXM in
normal human KC (data not shown).
Discussion
Our result clearly showed that RXM suppressed CCL17
production in HaCaT KC, which is a strong evidence for
its action against Th2-type reactions. These findings sup-
port its clinical effectiveness against Th2-type inflam-
mations, such as asthma and eosinophilic pustular
folliculitis.1
TNFa has been reported to cause the activation of var-
ious signaling molecules including NFkB (Duh et al, 1989),
ERK, JNK, and p38 MAP kinases (Kyriaskis et al, 1994), and
EGFR (Donato et al, 1989) in many cell types. In HaCaT
KCs, TNFa also activates signaling molecules such as ERK,
JNK, and p38 MAP kinases (Holvoet et al, 2003), and NFkB
Figure5
Roxithromycin (RXM) suppressed p38 mitogen-
activated protein kinase (MAPK) phosphorylation
induced by tumor necrosis factor (TNF)a and in-
terferon (IFN)c. HaCaT keratinocytes (KC) were
starved of fetal calf serum (FCS) for 24 h with or
without RXM, stimulated with TNFa and IFNg, and
harvested after the indicated time periods. Cell
lysates were subjected to western blotting. Stimu-
lation of HaCaT KC with TNFa and IFNg caused the
phosphorylation of ERK and p38 in a time-depend-
ent manner. Phosphorylation of p38 was attenuated
by the addition of RXM (a), which showed significant
suppression at 30 min when quantified with an
image analyzer (b). Phosphorylation of ERK was
also attenuated by the addition of RXM (c), which
showed significant suppression at 5 min when
quantified with the image analyzer (d). Data in the
graphs are expressed as the means of triplicates
(po0.05, po0.01).
1Suzuki S: Personal communication.
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(Tomic-Canic et al, 1998). IFNg activates STAT, ERK, and
p38 MAP kinases, but not JNK in several cell types (Goh
et al, 1999), (Nguyen et al, 2000). In our experiment, co-
stimulation with TNFa and IFNg of HaCaT KC caused the
synergistic upregulation of TARC. It also caused the phos-
phorylations of ERK, p38 and JNK MAP kinases, the EGFR
and STAT1, and degradation of IkB in a time-dependent
manner. TNFa alone caused the phosphorylations of ERK,
JNK, p38 MAP kinases, and the EGFR, and degradation of
IkB, whereas IFNg alone caused only STAT1 phosphorylat-
ion and very weak phosphorylation of p38 within 1 h, among
the above molecules investigated (data not shown). The
mechanism of synergy is unclear; however, Fujii-Maeda et al
(2004) recently reported that E-cadherin is essential in the
production of TARC/CCL17 in HaCaT KC, whose expres-
sion is upregulated by IFNg and it could be involved in
synergistic induction by TNFa and IFNg. TNFa is also ca-
pable of inducing the IFNg receptor, thereby inducing the
synergistic activation of indoleamine deoxygenase by TNFa
and IFNg (Robinson et al, 2003). The interaction of signaling
molecules, such as STAT1 and NFkB, is also a possible
mechanism of synergy, as reported in the transcriptional
activation of CXCL9 (Hiroi and Ohmori, 2003); however,
dominant negative STAT1-transfected cells showed a re-
sponse similar to wild-type STAT1-transfected cells, sug-
gesting that STAT1 activation is not essential in the
induction of TARC/CCL17 production. Interferon regulatory
factors (IRF) are the transcription factors involved in IFNg
signaling, and have been reported to interact with NFkB,
which causes the synergistic induction of inducible nitric
oxide synthase (Saura et al, 1999) and regulated on
activation, normal T-cell expressed and secreted (RANTES)
(Genin et al, 2000). IRF-1, the main IRF family member in
IFNg signaling, however, is induced through STAT1 signa-
ling, which should be STAT1 dependent. Recent investiga-
tion revealed that a number of genes are regulated by IFNg
in a STAT1-independent manner. Among them are several
chemokines such as macrophage-inflammatory protein-1a
and monocyte chemoattractant protein 1 (MCP-1) (Gil et al,
2001). Several transcription factors such as EGR-1, C/EBPb,
and c-jun are induced in STAT-1 null cells (Ramana et al,
2001). Production of TARC by TNFa and IFNg could be in-
duced through STAT1-independent pathways, the mecha-
nism of which needs further investigation. Recently, Banno
et al (2003, 2004) reported on a wide spectrum of genes
regulated by TNFa or IFNg utilizing a DNA microarray
system. TNFa and IFNg are pro-inflammatory cytokines
involved in innate immunity and inflammation, and the
synergistic effect of these cytokines would be a substan-
tial driving force of immunity and inflammation in a biolog-
ical context. The fact that TARC/CCL17 is only slightly
induced by TNFa or IFNg alone, and strongly induced
when they are applied at the same time, suggests that
TARC would have a biological meaning, especially when
inflammation reaches the level at which both TNFa and
IFNg are abundant, and, at such a level, TARC may have
the role of directing the inflammation in a Th2-balanced
direction.
The EGFR tyrosine phosphorylation inhibitor enhanced
the production of CCL17 stimulated by TNFa and IFNg. A
similar phenomenon has been reported with other chemo-
kines such as CCL2 (MCP-1), CCL5 (RANTES), and CXCL10
(interferon-g-induced protein of 10 kDa, IP-10) in normal
human KC (Mascia et al, 2003). EGFR is known to activate
various signaling cascades such as ERK, PI3K, and STATs
(STAT1, 3, 5). The finding that the EGFR inhibitor enhanced
the production of CCL17, whereas the ERK inhibitor had no
effect means that the activated EGFR exerts its signal
through signaling molecules other than ERK to inhibit
CCL17 production. The mechanism of CCL17 production
enhancement by the EGFR inhibitor needs further investi-
gation.
Our experiment showed that the mechanisms of CCL17
production in HaCaT and normal human KC are dependent
on NFkB activation. This is consistent with a previous re-
port, in which the NFkB inhibitor, MG-132, and mutant IkBa
introduced by retroviral vectors inhibited the production of
CCL17 in A549 cells, a bronchial epithelial cell line (Berin
et al, 2001). Our results also indicate that CCL17 production
in HaCaT and normal human KC is dependent on p38
MAPK, but not on ERK MAPK, which is also activated
in HaCaT KC stimulated by TNFa and IFNg. A recent
study reported on the involvement of p38 and NFkB
in CCL17 production in B cells (Nakayama et al, 2004),
which suggests similar signaling pathways of CCL17 pro-
duction in B cells and HaCaT KC. Increasing evidence
suggests an important role for p38 in adhesion-induced
differentiation and signal transduction in epithelial cells.
E-cadherin forms adherens junctions in epithelial tissues,
providing tight cell–cell contacts. E-cadherin engage-
ment is essential in the activation of p38 in intestinal
epithelial cells, which plays a crucial role in intestinal
epithelial cell differentiation (Laprise et al, 2002). P38
is also involved in the hypotonic stress-induced expression
of E-cadherin in HaCaT KC (Kippenberger et al, 2005).
Taking into consideration the fact that E-cadherin is essen-
tial in the spontaneous production of TARC/CCL17 (Fujii-
Maeda et al, 2004), and that its expression is induced by
IFNg, p38 may be involved in E-cadherin expression in-
duced by IFNg or in signaling pathways evoked by E-cad-
herin engagement.
Our results also showed that RXM partially inhibited
TNFa- and IFNg-induced NFkB activation in HaCaT KC,
which can explain the inhibitory effect of RXM on CCL17
production in our system. It has been reported that RXM
inhibited NFkB activation induced by reactive oxygen inter-
mediates (Abeyama et al, 2003) or by Propionibacterium
acnes (Chen et al, 2002). The inhibition by RXM of NFkB
activity induced by TNFa and IFNg was demonstrated in our
experiment.
Erythromycin has been reported to suppress cycloxy-
genase-2 synthesis in rheumatoid synovial cells by inhibit-
ing p38 activation (Fumimori et al, 2004). Clarithromycin
suppressed mucin production by inhibiting ERK phosphor-
ylation in the lungs in a murine model of DPB (Kaneko et al,
2003). Evidence of RXM inhibiting any of the MAP kinases,
however, has not been demonstrated. This report demon-
strates that RXM inhibits the phosphorylation of p38 in-
duced by TNFa and IFNg in KC.
This study, by demonstrating the signaling pathways
triggered by TNFa and IFNg in KC, and the mechanism of
RXM action, shed new light on the development of skin
REGULATION OF TARC PRODUCTION AND INHIBITION BY RXM 495125 : 3 SEPTEMBER 2005
inflammation, and also suggests some new therapeutic ap-
proaches to inflammatory skin diseases.
Materials and Methods
Antibodies and cytokines Anti-phospho-ERK1/2, anti-phospho-
JNK, anti-phospho-p38, anti-phospho-EGFR tyr845, anti-phos-
phoEGFR tyr992, anti-phosphoEGFR tyr1045, and anti-phospho-
EGFR tyr1068 were purchased from Cell Signaling (Beverly,
Massachusetts). Rabbit polyclonal anti-human IkBa antibody,
monoclonal mouse anti-ERK2, anti-JNK, anti-p38, anti-phospho-
STAT1, anti-STAT1a, anti-rabbit IgG horseradish peroxidase (HRP)
conjugate, and anti-mouse IgG HRP conjugate were from Santa
Cruz (Santa Cruz, California). Recombinant human TNFa and re-
combinant human IFNg were from R & D systems (Minneapolis,
Minnesota).
Signal transduction inhibitors Several signal transduction inhib-
itors were added 1 h before stimulation with TNFa and IFNg.
PD98059 was purchased from Alexis Biochemicals (San Diego,
California), PD153035, Parthenolide, Bay 11-7085, and SB202190
were purchased from Calbiochem (San Diego, California).
Cell culture HaCaT KC were a generous gift from Dr Kuroki
(Showa University, Tokyo, Japan) with the permission of Dr Fusenig
(Institute Fur Zell- und Tumourbiologie, Deutsches Kresforschungs-
zentrum, Heidelberg, Germany). They were grown routinely in
Eagle’s minimum essential medium (MEM, SIGMA, St. Louis, Mis-
souri) supplemented with 10% fetal calf serum (FCS) in a humid-
ified CO2 incubator. Cells of the 30th to 50th passage were used for
experiments.
Normal neonatal foreskin human KC were purchased from
Clonetics (San Diego, California), and cultured in keratinocyte-SFM
supplemented with BPE and EGF, from Invitrogen (Carlsbad,
California).
ELISA HaCaT KC were trypsinized into six-well plates. When they
reached subconfluency, the medium was changed to MEM without
FCS. After incubation in MEM without FCS for 24 h, RXM (provided
by Eisai, Tokyo, Japan) at a concentration of 104 to 108 M was
added prior to the addition of with 10 ng per mL TNFa and 100 U
per mL IFNg. Supernatants were harvested after 24 h and sub-
jected to ELISA utilizing 96-well plates coated with a murine
monoclonal antibody against human CCL17 (TECHNE, Minneapo-
lis, Minnesota). ELISA was performed according to the manufac-
turer’s directions. Briefly, samples and standards were applied to
antibody-coated 96-well plates, incubated for 2 h, washed, incu-
bated with secondary conjugated antibodies for another 2 h,
washed again, and incubated with substrate for 30 min before the
reaction was terminated. The optical density of each well was de-
termined using a microplate reader (Model 550, Bio-Rad, Hercules,
California) set to 450 nm.
Recombinant adenovirus Adenovirus vectors containing the
genes for HA-tagged wild-type STAT1 (AxCAwtSTAT1) and HA-
tagged dominant-negative STAT1 (AxCAdnSTAT1) (Nakajima et al,
1996), which contain a CAG promoter (chicken b-actin promoter
withCMV enhancer), were prepared by homologous recombination
in 293 cells as described previously (Hanakawa et al, 2000). DNA
encoding wtSTAT1 and dnSTAT1 were kind gifts from Dr Nakajima
of Osaka University. HaCaT KC were infected with AxCAwtSTAT1
or AxCAdnSTAT1, at a multiplicity of infection (MOI) of 10 in MEM
containing 10% FBS. They were starved of serum for 24 h, and
incubated with or without TNFa (10 ng per mL) and IFNg (100 U per
mL) for 24 h. Concentrations of TARC/CCL17 in supernatants were
examined by ELISA. The concentration of TARC/CCL17 was nor-
malized with the protein amount because of the anti-proliferative
effect of the STAT1 wild-type vector.
Luciferase assay The luciferase construct containing four NFkB
consensus sequences in tandem and the CMV–renilla luciferase
construct were purchased from Promega (Madison, Wisconsin).
HaCaT KCs were trypsinized into 100 mm dishes, and cultured
in MEM with 10% FCS until subconfluent. The NFkB–luciferase
(NFkB–luc) construct together with the CMV–renilla construct
were co-transfected using Fugene6 from Roche Diagnostics
(Tokyo, Japan) as recommended by the manufacturer. Six hours
after transfection, cells were trypsinized into six-well plates to
remove the toxic effect of Fugene6, and incubated overnight
before being stimulated with TNFa and IFNg. RXM (20 mg per mL)
was added 2 h before treatment with TNFa (10 ng per mL) and
IFNg (100 U per mL), and the cells were harvested after 16 h
of incubation. The cells were disrupted with lysis buffer provided
by the manufacturer, and then subjected to a dual-luciferase
assay (Promega) with a luminometer (Luminescencer-PSN, AB-
2200, ATTO, Tokyo, Japan) as described by the manufacturer.
Western blotting HaCaT KC or normal human KC pre-incubated
overnight with or without RXM (20 mg per mL) were stimulated
with TNFa (10 ng per mL) and IFNg (100 U per mL), and disrupted
in lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1
mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
and 1 mM b-glycerophosphate) with 2 mM phenyl methyl sulfonyl
fluoride (PMSF) (Boehringer Mannheim, Germany), 1 mg per mL
leupeptin (Sigma-Aldrich, St. Louis, Missouri), and 1 mM sodium
orthovanadate (Na3VO4) from Sigma-Aldrich. The concentra-
tions of the extracted proteins were measured using a BCA
Protein Assay Kit (Pierce, Rockford, Illinois). The samples were
boiled in sample buffer (50 mM Tris (pH 7.4)/0.14% sodium do-
decylsulfate (SDS)/1% b-mercaptoethanol (vol/vol)), and separated
by 12.5% SDS-polyacrylamide gel electrophoresis (10 mg of
protein per lane). After transfer to an Immobilon-P transfer mem-
brane (Millipore, Billerica, Massachusetts), the membrane was
incubated in blocking buffer (5% bovine serum albumin in
25 mM Tris/0.02% KCl/0.8% NaCl (pH 7.4) tris-buffered saline
(TBS)) for 1 h at 41C, followed by an appropriate primary anti-
body overnight at 41C. The membrane was washed and incub-
ated with a secondary antibody for 1 h, and the bands were
visualized using a chemiluminescence method (Phototope-HRP
Western Blot Detection Kit, New England BioLabs, Beverly,
Massachusetts).
Supplementary Material
The following supplementary material is available for this article online.
Figure S1
TNFa and IFNg induced phosphorylation of the EGF receptor, which
was completely abolished with the addition of PD153035.
Figure S2
Phosphorylations of JNK and STAT1 were not attenuated by the ad-
dition of RXM.
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